Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics, Inc. (Nasdaq: FBLG) is a clinical-stage biotechnology company based in Houston that focuses on developing fibroblast-based therapies and fibroblast-derived materials for chronic diseases. News about FibroBiologics often centers on progress in its pipeline, intellectual property developments, and financing activities that support its research and clinical plans.
Company updates include announcements on preclinical and clinical milestones, such as HREC approval in Australia for a Phase 1/2 trial of CYWC628 in diabetic foot ulcers and the filing of a Phase 1/2 IND application with the U.S. FDA for CYPS317 in moderate to severe psoriasis. FibroBiologics also reports preclinical data for programs like CYMS101 for multiple sclerosis and FSdC spheroid therapies for degenerative disc disease, as well as work in bone marrow organoids for cancer and human longevity applications.
Investors following FBLG news will also see coverage of patent filings and intellectual property expansions, including a U.S. patent application for fibroblast-derived spheroids for cartilage and joint repair, and disclosures about the company’s portfolio of more than 270 issued and pending patents. Capital markets news features registered direct offerings, concurrent private placement warrants, and the use of a Standby Equity Purchase Agreement, along with updates on the payoff of outstanding convertible debt.
This news feed aggregates these types of developments in one place, from clinical and scientific updates to proxy statements, Nasdaq compliance notices, and financing transactions. Readers can use it to monitor FibroBiologics’ progress across its fibroblast-based platforms and to track regulatory, corporate, and capital markets events that may affect the FBLG stock.
FibroBiologics (Nasdaq: FBLG) announced that Chairman & CEO Pete O’Heeron will present on the main stage at the A4LI H-SPAN Summit, June 29–July 1, 2026, at Georgetown University.
The three-day summit combines longevity research, innovation policy, and a Congressional Briefing to advance healthier human lifespans and policy advocacy.
FibroBiologics (Nasdaq: FBLG) announced issuance of Canadian Patent No. 3118732 for “Treatment of Cachexia Using Fibroblast Cells and Products Thereof.” The patent covers composition and method claims for immune-modulating fibroblasts, stem-marker-expressing cells, and multiple dosing routes to address cachexia and related inflammation.
The filing highlights claims on marker-positive fibroblasts and methods to reduce inflammation and prevent or reverse weight loss in patients with cachexia; the company cites a cancer cachexia market projection of $3.2B by 2032.
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the DealFlow Discovery Conference in Atlantic City on January 28-29, 2026. The company presentation is scheduled for 11:30 a.m. ET on January 29, 2026. FibroBiologics is a clinical-stage biotechnology company focused on therapeutics using fibroblasts and fibroblast-derived materials and holds 270+ patents issued and pending. Management will be available for one-on-one investor meetings during the event and provided contact details for further information.
FibroBiologics (Nasdaq: FBLG) outlined 2025 progress across clinical, manufacturing, IP, corporate and financing milestones.
Key items: opened a >10,000 sq ft Houston lab for discovery and in-house manufacturing; completed FDA cGMP master and working cell banks for CYWC628; received HREC approval in Australia for a 120-patient Phase 1/2 CYWC628 diabetic foot ulcer trial starting Q1 2026 with interim results potentially mid-2026 and topline before end-2026; filed an IND for CYPS317 on Dec 30, 2025; advanced remyelination and bone marrow organoid preclinical data; portfolio exceeds 270 issued and pending patents.
Financing: multiple registered direct offerings in Nov–Dec 2025 including $4M, $1.5M, $1.7M, closed two tranches of a $25M financing by Q2, and paid off all outstanding debt.
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference on January 11, 2026 in San Francisco.
The company presentation is scheduled for 4:30 p.m. PT on Sunday, January 11, 2026 at The St. Regis. Interested parties may visit the company website or contact info@fibrobiologics.com for more information.
FibroBiologics (Nasdaq: FBLG) reported positive preclinical results for an investigational FSdC spheroid therapy in animal models of degenerative disc disease dated January 5, 2026. Key findings at 12 weeks showed the highest intervertebral disc height recovery versus 2D fibroblasts and fibroblast spheroids, with an unadjusted p-value of 0.00015 for FSdC (compared with 0.036 and 0.068 for comparators).
The study showed sustained highest average disc size index (%DHI) across six measurement periods over 12 weeks. The company says it will pursue regulatory engagement and advance FSdC toward clinical development.
FibroBiologics (Nasdaq: FBLG) filed a Phase 1/2 IND application with the U.S. FDA on Dec 31, 2025 to seek clearance to start first-in-human trials of CYPS317, an allogeneic fibroblast spheroid therapy for moderate to severe psoriasis.
The submission includes preclinical pharmacology, safety, and manufacturing data; animal studies showed a single dose of CYPS317 matched or exceeded multiple doses of anti-IL-23 antibodies and reduced disease recurrence. The company says it aims to advance clinical development and pursue IND clearance for all four product candidates in 2026.
FibroBiologics (Nasdaq: FBLG) announced on Dec 16, 2025 the closing of a registered direct offering of 5,227,275 shares at $0.33 per share and a concurrent private placement of unregistered warrants to purchase up to 5,227,275 shares at an exercise price of $0.33. Aggregate gross proceeds were approximately $1.7 million, before placement agent fees and expenses; potential additional gross proceeds from full warrant exercise are approximately $1.7 million. Warrants become exercisable only after company stockholder approval and expire five years after such approval. Net proceeds will be used for working capital and general corporate purposes.
FibroBiologics (Nasdaq: FBLG) announced a registered direct offering of 5,227,275 shares at $0.33 per share and a concurrent private placement of unregistered warrants exercisable into up to 5,227,275 shares at $0.33. Gross proceeds from the registered offering are expected to be approximately $1.7 million, before fees and expenses, with potential additional proceeds of ~$1.7 million if warrants are fully exercised on a cash basis. Closing is expected on or about December 16, 2025, subject to customary conditions and stockholder approval for warrant exercise shares. H.C. Wainwright is sole placement agent. Proceeds are intended for working capital and general corporate purposes. The registered shares are offered under an effective Form S-3 registration statement.
FibroBiologics (Nasdaq: FBLG) on December 10, 2025 filed a U.S. patent application titled “Spheroids For Cartilage Repair” for a proprietary fibroblast-derived therapy platform targeting orthopedic and musculoskeletal conditions.
The filing seeks protection for use of fibroblast cells, spheroids, and fibroblast-differentiated chondrocyte spheroids in degenerative disc repair, cartilage repair, and joint restoration. The company noted preclinical studies showing integration with native tissue, extracellular matrix remodeling, and regeneration in disc and joint degeneration models. FibroBiologics reported a portfolio of 270+ patents issued and pending. The company said the patent, if granted, would broaden protection across multiple orthopedic indications.
FAQ
What is the current stock price of Fibrobiologics (FBLG)?
What is the market cap of Fibrobiologics (FBLG)?
